The text explores the theme of Brazilian sufficiency in vaccines. It presents the ways practiced in the two most important Brazilian institutions in the development and production of vaccines - the Butantan Institute and the Institute of Technology in Immunobiologicals (Bio-Manguinhos). These paths are the pure and simple purchase, the purchase of the product with technology transfer commitment, partnerships that include the fulfillment of phase 3 trials by the buyer, the new path announced by Instituto Butantan in which the partnership includes for the realization of trials in phases 1 and 2 and, finally, the invention, development and local vaccine production. The latter is only mentioned as a possibility currently not achieved. Finally, the text presents data on the chances of success in vaccine development.
